The anti-vascular endothelial growth factor (VEGF) mAb bevacizumab, the first anti-angiogenic agent in the market, was approved in 2004 for CRC patients, although several trials showed modest improvements in survival. This evidence concerns the gene VEGFA and colorectal carcinoma.